Company profile: BiPar Sciences
1.1 - Company Overview
Company description
- Provider of PARP inhibitor-based cancer therapies, developing BSI-201, an experimental PARP inhibitor in mid-stage trials for advanced breast cancer, ovarian cancer, and other tumors; based in Brisbane, CA.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BiPar Sciences
ProstaGene
HQ: United States
Website
- Description: Provider of biotechnology solutions integrating proprietary molecular diagnostics with novel therapeutic screening and commercial experience to develop novel cancer treatments, based on the patents of founder Dr. Richard G. Pestell; early-stage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProstaGene company profile →
OncoSynergy
HQ: United States
Website
- Description: Provider of Resistance Mechanism Inhibitors (RMIs) targeting multiple cancer-driving pathways to address resistance, including OS2966, a monoclonal antibody against CD29 to inhibit cancer growth, invasiveness, and resistance. Conducting a Phase 1 trial in recurrent glioblastoma evaluating OS2966 delivered directly to the brain via convection-enhanced delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoSynergy company profile →
Oncocyte
HQ: United States
Website
- Description: Provider of blood-based and gene expression tests and biopharma services: DetermaCNI detects cancer progression early via cell-free DNA instability; DetermaIO assesses the tumor immune microenvironment to identify immunotherapy benefit; VitaGraft Kidney/Liver quantify donor-derived cell-free DNA to monitor transplant health and detect rejection; GraftAssure uses droplet digital PCR; and tissue- and blood-based biomarker-driven clinical trial support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncocyte company profile →
Umoja Biopharma
HQ: United States
Website
- Description: Provider of next-generation immunotherapies intended to combat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Umoja Biopharma company profile →
TomoTherapy
HQ: United States
Website
- Description: Provider of advanced radiation therapy solutions that are developed, manufactured, distributed, marketed and sold for treating a wide variety of cancers. Its ring gantry-based TomoTherapy platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TomoTherapy company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BiPar Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BiPar Sciences
2.2 - Growth funds investing in similar companies to BiPar Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BiPar Sciences
4.2 - Public trading comparable groups for BiPar Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →